Faes Farma

Growth story remains attractive

28/05/26 -"Backed by life cycle management of some of its key products, expansion into LatAm, a rebound of the animal healthcare business, and the recent acquisitions, Faes is well positioned to grow at a ..."

PDF page sample
Pages
44
Language
English
Published on
28/05/26
Download
You may also be interested by these reports :
01/06/26
At a time when a lot of Big Pharmas are losing sleep because of looming patent expirations over the next five years, the likes of Sandoz (REDUCE; ...
30/05/26
With Sandoz being a pioneer and amongst the handful of firms with true biosimilar development capability, manufacturing expertise in complex ...
28/05/26
Backed by life cycle management of some of its key products, expansion into LatAm, a rebound of the animal healthcare business, and the recent ...
27/05/26
Our target price has been revised upwards, driven by multiple Phase III readouts anticipated in 2026, expansion of the late-stage pipeline, and the ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO